MaaT Pharma (France) has raised €10M in a series A round, which will allow it to start clinical development of its autologous therapy for imbalance of the Gut Microbiome.

maat_microbiome_autologous_therapy_fmtMaaT Pharma is developing microbiome-based therapies with an autologous (self-sourced) approach. This means that the patient suffering from dysbiosis is treated with their own microbiome, samples of which were stored when the patient was healthy.

Dysbiosis is an imbalance in the normal microbiota living in the human gut that can lead to difficult opportunitistic infections.

ADVERTISEMENT

Since its creation in late 2014, MaaT Pharma has attracted significant attention. This Lyon-based startup had already received €2M from the world-first €160M Microbiome Fund, and developed its pre-clinical proof of concept in collaboration with the French National Institute of Agricultural Research (INRA).

maat_microbiome_dysbiosis_microbiotherapy

Fig 1: Types of dysbiosis and treatment with FMT or bacteriotherapy (microbiotherapy).

MaaT has also won the ‘iiAwards’ startup competition and was selected for the TOP10 in the Big Booster programme.

MaaT Pharma has now raised an additional €10M, from its previous investors (Seventure and INRA Transfert) and two new investors, the CM-CIC (who also invested in other cool French startups) and Biocodex (France), a pharma that is already developing probiotics and therapies in gastroenterology.

The new funds will help MaaT enter clinical trials with its current projects. These include the therapy itself (MaaT001), which is a type of fecal microbiota transplantation (FMT), as well as a prototype to safely collect and store stool samples (MaaT002).

maat_pharma_biocodex_CM-CIC

Current investors in MaaT Pharma.

For CM-CIC (one of the new investors), a key factor for its interest in MaaT was that they combined an autologous therapy with an an industrial, quantifiable and reproducible process – a challenge for the industry.

While autologous therapies carry less risks of medical complications (like immune rejection), these strategies face significant challenges in manufacturing and logistics – something that has been discussed a lot in the CAR-T field, for example, with great arguments supporting universal approaches.

Upcoming clinical trials will study patients that developed dysbiosis after treatments (that can hurt the microbiome) for leukemia or bone and joint infections. So, collection of microbiome samples would happen before these treatments were carried out.

MaaT Pharma seems to have its autologous strategy well thought-out, which has therefore granted them important financial backing. This startup could really become an important player in the emerging Microbiome field. 


MaaT’s explanation of its microbiotherapy:


Featured image credit: Glowing Cells Fractals © sakkmesterke (BigStock ID83259515)
Figure 1 credit: Brandt (2013). American Journal of Gastroenterology Lecture: Intestinal Microbiota and the Role of Fecal Microbiota Transplant (FMT) in Treatment of C. difficile Infection. The American Journal of Gastroenterology (doi: 10.1038/ajg.2012.450)
Previous post

Leading German Biotech Spins Off a New Startup in Autoimmune Diseases

Next post

Novel Antibody for Influenza gets FDA Fast-Track Approval

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.